2025 Annual Report
Annual Report
ECETOC publishes a framework for the risk assessment of plastic additives
Press Release

ECETOC publishes a framework for the risk assessment of plastic additives

Part 1 sets out the fundamental elements, from problem formulation to risk characterisation.Brussels, 22 July 2026. The ECETOC Plastic Additives Task Force has published the first of two peer...
January 2026 news from the Sec Gen
News

January 2026 news from the Sec Gen

Dear colleagues and friends,As we begin a new year, I would like to thank you for your continued engagement and trust in ECETOC. 2026 promises to be an exciting and dynamic year, and I am pleased...
HSSD Tool

HSSD Tool

This software was developed by a consortium of partners to facilitate the uptake of novel approaches to estimate aquatic threshold concentrations (e.g. the concentration at which 5% of the species are exposed above their EC50, HC5).
The Human Exposure Assessment Tools Database (heatDB)

The Human Exposure Assessment Tools Database (heatDB)

heatdb is a public directory of exposure data sources as well as available tools for exposure
NanoApp

NanoApp

ECETOC’s NanoApp is a tool designed to define the boundaries of sets of similar nanoforms and to generate a justification for the REACH registration.
Targeted Risk Assessment (TRA)

Targeted Risk Assessment (TRA)

The Targeted Risk Assessment (TRA) estimates exposures to workers, consumers and the environment that arise during a series of events.
Chronic fish case studies towards an IATA

Chronic fish case studies towards an IATA

Why?Hazard and safety assessments for the pelagic compartment often rely on in vivo studies using a single fish species, raising ethical concerns and uncertainty in terms of extrapolation....
Estimating the environmental release of Synthetic Polymeric Microparticles from Products

Estimating the environmental release of Synthetic Polymeric Microparticles from Products

Why?REACH restriction: SPM use restricted; emissions reporting required by May 2027. Gap: No analytical methods available to measure SPM emissions. Solution: Draft SPERC-based approac...
Case Studies on Reliability and Relevance Considerations during Validation of NAMs

Case Studies on Reliability and Relevance Considerations during Validation of NAMs

Why?Validation of NAMs is often overlooked despite its importance for regulatory use. Traditional validation methods are less suitable for NAMs, which focus on key events rather than apical...
Technical Report
29.11.2001

TR 081 – Human Acute Intoxication from Monochloroacetic Acid: Proposals for Therapy

TR 081 : Human Acute Intoxication from Monochloroacetic Acid: Proposals for Therapy | November 2001

The industrial chemical monochloroacetic acid (MCAA) is used mainly in carboxylation reactions. It is readily absorbed following oral or dermal exposure and can induce severe systemic intoxication.

A number of fatalities have been reported from accidental exposure in the workplace. Symptoms are delayed and develop one to four hours after exposure. Limited clinical data in humans and experimental data in rodents indicate that lactic acidosis is the main mechanism leading to toxic effects, death generally being due to cardiovascular shock, renal failure and cerebral oedema.

Following accidental skin contact with MCAA, it is essential that the skin is decontaminated as soon as possible. There is no clear experimental evidence that sodium bicarbonate solution is more effective than water for this purpose. With regard to antidotes for MCAA intoxication, dichloroacetate (DCA), and to a lesser extent phenobarbitone (PB), have been identified as effective in reducing mortality and decreasing lactate accumulation in the blood and cerebral spinal fluid of rats and mice.

Physicians from four European national poison control centres participated in a workshop (1997) on the use of DCA and PB in the treatment of MCAA intoxication. DCA was concluded to be the preferred antidote and a protocol for the treatment of MCAA intoxication was established.

This protocol, that has now been incorporated into the IPCS-INTOX Poison Information Monograph on MCAA, proposes the early administration of DCA (50mg/kg, iv) as specific antidote therapy to prevent the development of MCAA-induced lactic acidosis. In supporting this proposal, the ECETOC TF recommends that the availability of DCA should be improved in order to provide effective treatment in the event of accidental exposure to MCAA. If no DCA is available, treatment with PB might be considered, provided that intensive care facilities were available to monitor closely the treatment.